Perrigo completed the sale of its Dermacosmetics business to Karo Healthcare on April 30, 2026. The transaction includes an upfront cash payment of 305.6 million euros, which includes 5.6 million euros in net working capital adjustments. Perrigo may receive up to 27.0 million euros in additional contingent consideration based on performance milestones over the next three years. The divested business generated approximately 120 million euros in net sales in 2025 and represented about 5% of Perrigo's adjusted operating income. The divestiture is part of the company's 'Three-S' plan (Stabilize, Streamline, and Strengthen).